🚀 VC round data is live in beta, check it out!
Passage Bio Valuation Multiples
Discover revenue and EBITDA valuation multiples for Passage Bio and similar public comparables like RenovoRx, Karolinska Development, Werewolf Therapeutics, NeuroSense Therapeutics and more.
Passage Bio Overview
About Passage Bio
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
Founded
2017
HQ
Employees
60
Website
Financials (LTM)
EV
$427K
Passage Bio Financials
Passage Bio reported last 12-month revenue of —.
In the same LTM period, Passage Bio generated — in gross profit and had net loss of ($45M).
Revenue (LTM)
Passage Bio P&L
In the most recent fiscal year, Passage Bio reported revenue of — and EBITDA of ($42M).
Passage Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($42M) | XXX | XXX | XXX |
| Net Profit | ($45M) | XXX | ($46M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Passage Bio Stock Performance
Passage Bio has current market cap of $29M, and enterprise value of $427K.
Market Cap Evolution
Passage Bio's stock price is $9.08.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $427K | $29M | 0.0% | XXX | XXX | XXX | $-14.32 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPassage Bio Valuation Multiples
Passage Bio trades at 0.0x EV/EBITDA.
Passage Bio Financial Valuation Multiples
As of March 21, 2026, Passage Bio has market cap of $29M and EV of $427K.
Equity research analysts estimate Passage Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Passage Bio has a P/E ratio of (0.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $29M | XXX | $29M | XXX | XXX | XXX |
| EV (current) | $427K | XXX | $427K | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 0.0x | XXX | XXX | XXX |
| EV/EBIT | 0.0x | XXX | 0.0x | XXX | XXX | XXX |
| P/E | (0.6x) | XXX | (0.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 0.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Passage Bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Passage Bio Margins & Growth Rates
Passage Bio's revenue in the last fiscal year grew by —.
Passage Bio's revenue per employee in the last FY averaged $0.0M.
Passage Bio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (32%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Passage Bio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| RenovoRx | XXX | XXX | XXX | XXX | XXX | XXX |
| Karolinska Development | XXX | XXX | XXX | XXX | XXX | XXX |
| Werewolf Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| NeuroSense Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Reviva Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Passage Bio M&A Activity
Passage Bio acquired XXX companies to date.
Last acquisition by Passage Bio was on XXXXXXXX, XXXXX. Passage Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Passage Bio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPassage Bio Investment Activity
Passage Bio invested in XXX companies to date.
Passage Bio made its latest investment on XXXXXXXX, XXXXX. Passage Bio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Passage Bio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Passage Bio
| When was Passage Bio founded? | Passage Bio was founded in 2017. |
| Where is Passage Bio headquartered? | Passage Bio is headquartered in United States. |
| How many employees does Passage Bio have? | As of today, Passage Bio has over 60 employees. |
| Who is the CEO of Passage Bio? | Passage Bio's CEO is William Chou. |
| Is Passage Bio publicly listed? | Yes, Passage Bio is a public company listed on Nasdaq. |
| What is the stock symbol of Passage Bio? | Passage Bio trades under PASG ticker. |
| When did Passage Bio go public? | Passage Bio went public in 2020. |
| Who are competitors of Passage Bio? | Passage Bio main competitors are RenovoRx, Karolinska Development, Werewolf Therapeutics, NeuroSense Therapeutics. |
| What is the current market cap of Passage Bio? | Passage Bio's current market cap is $29M. |
| Is Passage Bio profitable? | No, Passage Bio is not profitable. |
| What is the current net income of Passage Bio? | Passage Bio's last 12 months net income is ($45M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.